BioAegis Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of Gelsolin, an Immune Regulator, for the Treatment of Acute Respiratory Distress Syndrome (ARDS)
22. Oktober 2024 00:30 ET
|
BioAegis Therapeutics
Global 600 patient study will evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. Rhu-pGSN is an immune system regulator that interrupts the...
BioAegis Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of Gelsolin, an Immune Regulator, for the Treatment of Acute Respiratory Distress Syndrome (ARDS)
17. Oktober 2024 08:07 ET
|
BioAegis Therapeutics
Global 600 patient study will evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. Rhu-pGSN is an immune system regulator that interrupts the...
Acute Respiratory Distress Syndrome Analysis Report 2024: A $2.36 Billion Market by 2032 from $1.23 Billion in 2023
18. Juli 2024 06:27 ET
|
Research and Markets
Dublin, July 18, 2024 (GLOBE NEWSWIRE) -- The "Acute Respiratory Distress Syndrome Market Report by Type, End User, Regions and Company Analysis 2024-2032" report has been added to ...
Acute Lung Injury Treatment Global Market Report 2023: R&D of Novel Therapies Enhancing Acute Lung Injury Treatment Growth
16. März 2023 08:18 ET
|
Research and Markets
Dublin, March 16, 2023 (GLOBE NEWSWIRE) -- The "Global Acute Lung Injury Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive...
BioAegis Therapeutics Announces FDA Clearance of IND for its ‘Inflammation Regulator Protein,’ Gelsolin, for the Treatment of ARDS
26. Januar 2023 14:05 ET
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage company developing therapies for inflammatory diseases through a portfolio built around plasma...
Insights on the Lung Injury Global Market to 2027 - Pipelines Drugs for Treatment of Acute Lung Injury Presents Opportunities
07. September 2022 05:33 ET
|
Research and Markets
Dublin, Sept. 07, 2022 (GLOBE NEWSWIRE) -- The "Global Lung Injury Market (2022-2027) by Therapy, Injury, End User, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis"...
BioAegis Therapeutics Announces Study Indicating Gelsolin Treatment Improves Survival and Reduces Lung Injury in Antibiotic Resistant Pneumonia
03. September 2020 21:42 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through...